FY26 Novel approaches to support therapeutic development in ultra-rare cancers
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- Joshua Holliday joshua.holliday@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration's Oncology Center of Excellence (OCE) is seeking novel research and development approaches to support therapeutic development for ultra-rare cancer treatments. The contract, categorized under Biotechnology Research and Development (NAICS 541714), aims to advance groundbreaking oncology research and drug development efforts. The estimated solicitation will be released on March 1, 2026, with an anticipated award date of May 1, 2026.
While specific budget details are not provided, the contract opportunity will be managed through the FDA's Scientific Collaborative Program, focusing on innovative therapeutic strategies for ultra-rare cancer research. The primary point of contact is Joshua Holliday (joshua.holliday@fda.hhs.gov) from the FDA, who can provide additional information about the potential contract. The opportunity is not set aside for any specific type of business, suggesting open competition among qualified research and development organizations in the biotechnology sector.
Forecast text
The Oncology Center of Excellence's (OCE's) Scientific Collaborative Program has led the way in supporting groundbreaking research efforts in oncology and drug development, contributing greatly to the FDA public health mission.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast